Fucoidan inhibits angiogenesis induced by multiple myeloma cells

Liu,Fen; Luo,Guoping; Xiao,Qing; Chen,Liping; Luo,Xiaohua; Lv,Jinglong; Chen,Lixue

doi:10.3892/or.2016.4987

Fucoidan inhibits angiogenesis induced by multiple myeloma cells

Authors:
- Fen Liu
- Guoping Luo
- Qing Xiao
- Liping Chen
- Xiaohua Luo
- Jinglong Lv
- Lixue Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, The Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: August 1, 2016 https://doi.org/10.3892/or.2016.4987
Pages: 1963-1972

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) remains an incurable hematological neoplasms. Our previous studies showed that Fucoidan possessed anti-myeloma effect by inducing apoptosis and inhibiting invasion of myeloma cells. In this study, we evaluated the effect of Fucoidan on angiogenesis induced by human myeloma cells and elucidated its possible mechanisms. Multiple myeloma cells were treated with Fucoidan at different concentrations, then the conditioned medium (CM) was collected. The levels of VEGF in the CM were tested by ELISA. The results showed that Fucoidan significantly decreased VEGF secretion by RPMI-8226 and U266 cells. The tube formation assay and migration test on human umbilical vein endothelial cells (HUVECs) were used to examine the effect of Fucoidan on angiogenesis induced by human myeloma cells. The results showed that Fucoidan decreased HUVECs formed tube structures and inhibited HUVECs migration, and suppressed the angiogenic ability of multiple myeloma RPMI-8226 and U266 cells in a dose-dependent manner. The study also showed that Fucoidan downregulated the expression of several kinds of proteins, which may be correlated with the reduction of angiogenesis induced by myeloma cells. Moreover, results were compared from normoxic and hypoxic conditions, they showed that Fucoidan had anti-angiogenic activity. Furthermore, in a multiple myeloma xenograft mouse model, it indicated that Fucoidan negatively affected tumor growth and angiogenesis in vivo. In conclusion, our results demonstrate that Fucoidan was able to interfere with angiogenesis of multiple myeloma cells both in vitro and in vivo and may have a substantial potential in the treatment of MM.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Röllig C, Knop S and Bornhäuser M: Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar
3	Ribatti D, Mangialardi G and Vacca A: Antiangiogenic therapeutic approaches in multiple myeloma. Curr Cancer Drug Targets. 12:768–775. 2012. View Article : Google Scholar : PubMed/NCBI
4	Gacche RN and Meshram RJ: Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol. 113:333–354. 2013. View Article : Google Scholar : PubMed/NCBI
5	Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, et al: Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 119:5782–5794. 2012. View Article : Google Scholar : PubMed/NCBI
6	Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, Sivridis E and Gatter KC: Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res. 30:2831–2836. 2010.PubMed/NCBI
7	Medinger M, Fischer N and Tzankov A: Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol. 2010:7297252010. View Article : Google Scholar : PubMed/NCBI
8	Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J, Zhao W, Chu DK and Wiedemann P: Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci. 50:1873–1879. 2009. View Article : Google Scholar
9	Han YS, Lee JH and Lee SH: Antitumor effects of Fucoidan on human colon cancer cells via activation of Akt signaling. Biomol Ther (Seoul). 23:225–232. 2015. View Article : Google Scholar
10	Delma CR, Somasundaram ST, Srinivasan GP, Khursheed M, Bashyam MD and Aravindan N: Fucoidan from Turbinaria conoides: A multifaceted 'deliverable' to combat pancreatic cancer progression. Int J Biol Macromol. 74:447–457. 2015. View Article : Google Scholar
11	Yoshimoto M, Higaki K, Nanba E and Ikeguchi M: Anti-proliferation activity of Fucoidan in MKN45 gastric cancer cells and downregulation of phosphorylated ASK1, a cell cycle-regulated kinase. Yonago Acta Med. 58:1–7. 2015.PubMed/NCBI
12	Zhu C, Cao R, Zhang SX, Man YN and Wu XZ: Fucoidan inhibits the growth of hepatocellular carcinoma independent of angiogenesis. Evid Based Complement Alternat Med. 2013:6925492013. View Article : Google Scholar : PubMed/NCBI
13	Xue M, Ge Y, Zhang J, Wang Q, Hou L, Liu Y, Sun L and Li Q: Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PLoS One. 7:e434832012. View Article : Google Scholar : PubMed/NCBI
14	Lv J, Xiao Q, Wang L, Liu X, Wang X, Yang Z, Zhang H and Dong P: Fucoidan prevents multiple myeloma cell escape from chemotherapy-induced drug cytotoxicity. Fitoterapia. 84:257–263. 2013. View Article : Google Scholar
15	Yang YC, Chen PN, Wang SY, Liao CY, Lin YY, Sun SR, Chiu CL, Hsieh YS, Shieh JC and Chang JT: The differential roles of Slit2-exon 15 splicing variants in angiogenesis and HUVEC permeability. Angiogenesis. 18:301–312. 2015. View Article : Google Scholar : PubMed/NCBI
16	Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Munshi N, Hideshima T, Chauhan D, et al: Targeting PKC in multiple myeloma: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 109:1669–1677. 2007. View Article : Google Scholar
17	Kwak JY: Fucoidan as a marine anticancer agent in preclinical development. Mar Drugs. 12:851–870. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chen H, Shi L, Yang X, Li S, Guo X and Pan L: Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol. 92:587–597. 2010. View Article : Google Scholar : PubMed/NCBI
19	Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, et al: A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24:229–241. 2013. View Article : Google Scholar : PubMed/NCBI
20	Minoia C, Quero C, Asselti M, Galise I, Marzano AL, Iacobazzi A, Rana A, Merchionne F, Serratì S, De Tullio G, et al: Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas. Br J Haematol. 163:640–645. 2013. View Article : Google Scholar : PubMed/NCBI
21	Drolle H, Wagner M, Vasold J, Kütt A, Deniffel C, Sotlar K, Sironi S, Herold T, Rieger C and Fiegl M: Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. Leuk Res. 39:779–785. 2015. View Article : Google Scholar : PubMed/NCBI
22	Huelsemann MF, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker HJ, Theurich S, von Bergwelt-Baildon M, Pallasch CP, et al: Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia. 29:981–984. 2015. View Article : Google Scholar
23	Muz B, de la Puente P, Azab F, Luderer M and Azab AK: Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 4:e2622014. View Article : Google Scholar : PubMed/NCBI
24	Hashimoto T and Shibasaki F: Hypoxia-inducible factor as an angiogenic master switch. Front Pediatr. 3:332015. View Article : Google Scholar : PubMed/NCBI
25	Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, et al: Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 27:1697–1706. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fan GC: Hypoxic exosomes promote angiogenesis. Blood. 124:3669–3670. 2014. View Article : Google Scholar : PubMed/NCBI
27	Chen TL, Zhu GL, Wang JA, Wang Y, He XL and Jiang J: Apoptosis of bone marrow mesenchymal stem cells caused by hypoxia/reoxygenation via multiple pathways. Int J Clin Exp Med. 7:4686–4697. 2014.
28	Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V and Bonati A: Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 18:628–635. 2004. View Article : Google Scholar : PubMed/NCBI
29	Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B and Vanderkerken K: Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: Study in the 5T33MM model. Br J Cancer. 90:1076–1083. 2004. View Article : Google Scholar : PubMed/NCBI